Free Trial

Entain (ENT) Stock Forecast & Price Target

Entain logo
GBX 707.60 -6.00 (-0.84%)
(As of 12/20/2024 12:01 PM ET)

Entain - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
3
Buy
3

Based on 6 Wall Street analysts who have issued ratings for Entain in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 6 analysts, 3 have given a hold rating, and 3 have given a buy rating for ENT.

Consensus Price Target

GBX 1,077.25
According to the 6 analysts' twelve-month price targets for Entain, the average price target is GBX 1,077.25. The highest price target for ENT is GBX 1,140, while the lowest price target for ENT is GBX 1,010. The average price target represents a forecasted upside of 52.24% from the current price of GBX 707.60.
Get the Latest News and Ratings for ENT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Entain and its competitors.

Sign Up

ENT Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
5 Buy rating(s)
8 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
2 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetGBX 1,077.25GBX 1,025.80GBX 1,124.83GBX 1,463
Consensus Rating
Moderate Buy
Hold
Moderate Buy
Moderate Buy

ENT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ENT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Entain Stock vs. The Competition

TypeEntainConsumer Cyclical Companies
Consensus Rating Score
2.50
2.67
Consensus RatingModerate BuyModerate Buy
News Sentiment Rating
Neutral News

See Recent ENT News
Neutral News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/16/2024Jefferies Financial Group
2 of 5 stars
 Reiterated RatingBuyGBX 1,140+50.40%
11/7/2024Berenberg Bank
2 of 5 stars
 Lower TargetNeutralGBX 1,030 ➝ GBX 1,010+35.03%
9/11/2024JPMorgan Chase & Co.
3 of 5 stars
 Reiterated RatingNeutral
9/9/2024Shore Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy
4/18/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,089+33.19%
2/6/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual WeightGBX 1,120 ➝ GBX 1,070+10.84%
11/27/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeSellGBX 1,450 ➝ GBX 820-2.38%
9/27/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuyGBX 2,200 ➝ GBX 1,600+69.31%
3/9/2023Numis Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuyGBX 1,900+41.97%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 11:16 PM ET.


ENT Forecast - Frequently Asked Questions

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Entain is GBX 1,077.25, with a high forecast of GBX 1,140 and a low forecast of GBX 1,010.

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Entain in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ENT shares.

According to analysts, Entain's stock has a predicted upside of 52.24% based on their 12-month stock forecasts.

Entain has been rated by research analysts at Berenberg Bank, and Jefferies Financial Group in the past 90 days.

Analysts like Entain less than other "consumer cyclical" companies. The consensus rating score for Entain is 2.50 while the average consensus rating score for "consumer cyclical" companies is 2.67. Learn more on how ENT compares to other companies.


This page (LON:ENT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners